Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06376669 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Stereotactic Body Proton Therapy for Treatment of Primary Renal Cell Carcinoma

Study acronym: SPARE
StatusRecruiting
PhasePhase 2
Started2025-02-25
View on ClinicalTrials.gov ↗

Amendment history

2026-04-02
Study Status v6
Re-verified, no change to tracked fields
2025-03-25
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v5
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2025-03→confirmed 2025-02-25
Study sites0→1
2025-02-10
Study Status v4
Start date2025-01→2025-03
2024-12-19
Study Status v3
Start date2024-12→2025-01
2024-09-30
Study Status, Sponsor/Collaborators v2
Start date2024-08→2024-12
Collaborators+40 characters
Robert L. Sloan Fund for Cancer Research
2024-07-08
Study Status v1
Start date2024-06→2024-08
2024-04-18
Original filing
This study examines the impact of proton based stereotactic radiation therapy (SBRT) on kidney function as well as other oncologic outcomes including local control, locoregional and systemic failure, progression free and overall survival.
Trial Details
NCT Number NCT06376669
Lead Sponsor Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators: Robert L. Sloan Fund for Cancer Research
Conditions Renal Cell Carcinoma
Enrollment 20 participants
Start Date 2025-02-25
Primary Completion 2027-06 (estimated)
Study Completion 2030-08 (estimated)
Updated on ClinicalTrials.gov 2026-04-03